Early treatment-related mortality in adult autologous stem cell transplant recipients: A nation-wide survey of 1482 transplanted patients

European Journal of Haematology

Volumn 76, Issue 3, 2006, Pages 245-250

  Jantunen, E ^a   Itala M ^b   Lehtinen, T ^c   Kuittinen, O ^d   Koivunen, E ^c   Leppa S ^e   Juvonen, E ^e   Koistinen, P ^d   Wiklund, T ^e   Nousiainen, T ^a   Remes, K ^b   Volin, L ^e  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d OULU UNIVERSITY HOSPITAL   (Finland)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Autologous stem cell transplantation; Early; Infections; Organ toxicity; Treatment related mortality

Indexed keywords

ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BREAST CANCER; CARDIOTOXICITY; CAUSE OF DEATH; CHRONIC LYMPHATIC LEUKEMIA; EPIDEMIOLOGICAL DATA; FEMALE; FINLAND; HEALTH SURVEY; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; MYCOSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RECIPIENT; RISK ASSESSMENT; VIRUS INFECTION;

AMYLOIDOSIS; BREAST NEOPLASMS; CAUSE OF DEATH; DATA COLLECTION; FINLAND; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOMA; MULTIPLE MYELOMA; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 33645076801     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00605.x     Document Type: Article

References (36)

1. G ratwohl A S chmid O B aldomero H H orisberger B U rbano-ispizua A for the Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT) Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indication and impact of team density Bone Marrow Transplant 2004 34 855 875
2. D reger P S tilgenbauer S B enner A et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: a risk-matched analysis based on the VH gene mutational status Blood 2004 103 2850 2858
3. J abbour E K eating MJ C hamplin RE K houri IF Stem cell transplantation for chronic lymphocytic leukaemia: should not more patients get a transplant Bone Marrow Transplant 2004 34 289 297
4. M illigan DW F ernandes S D asgupta R et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses Blood 2005 105 397 404
5. D ispenzieri A K yle RA L acy MQ et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case control study Blood 2004 103 3960 3963
6. S kinner M S anchoralawala V S eldin DC et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: a 8-year study Ann Intern Med 2004 140 85 93
7. R apoport AP D ipersio JF M artin BA et al. Patients >40 years undergoing autologous or allogeneic BMT have regimen-related mortality rates and event-free survivals comparable to patients <40 years Bone Marrow Transplant 1995 15 523 530
8. F ouillard L L abopin M G ratwohl A et al. Outcome of 5651 hematopoietic stem cell transplants for haematological malignancies carried out in Europe in 1993: a reliability study of the registry Bone Marrow Transplant 2002 30 637 643
9. A tkinson K N ivison -S mith I H awkins T Haemopoietic stem cell transplantation in Australia, 1992-95: a report from the Australian Bone Marrow Transplant Recipient Registry Aust N Z J Med 1997 27 408 419
10. W eaver CH S chwarzberg LS H ainsworth J G reco FA L i W B uckner CD W est WH Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers Bone Marrow Transplant 1997 19 671 678
11. D amon LE H u WW S tockerl -G oldstein KE et al. High-dose chemotherapy and hematopoietic stem cell rescue in breast cancer: experience in California Biol Blood Marrow Transplant 2000 6 496 505
12. N ivison -S mith I B radstock KF D odds AJ H awkins PA S zer J Haemopoietic stem cell transplantation in Australia and New Zealand, 1992-2001: progress report from the Australasian Bone Marrow Transplant Recipient Registry Intern Med J 2005 35 18 27
13. B ergh J W iklund T E rikstein B et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial Lancet 2000 356 1384 1391
14. S tuart MJ P eters WP B roadwater G et al. High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes Biol Blood Marrow Transplant 2002 8 666 673
15. H olland HK D ix SP G eller RB et al. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care J Clin Oncol 1996 14 1156 1164
16. S temmer SM H ardan I R az H et al. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients Bone Marrow Transplant 2003 31 655 661
17. C omenzo RL G ertz MA Autologous stem cell transplantation for primary systemic amyloidosis Blood 2002 99 4276 4282
18. J antunen E S iitonen T P utkonen M K oivunen E N ousiainen T K oistinen P Autologous stem cell transplantation in patients with primary amyloidosis: a nation-wide survey Leuk Lymphoma 2004 45 2485 2489
19. G ertz MA L acy MQ D ispenzieri A et al. Stem cell transplantation for the management of primary systemic amyloidosis Am J Med 2002 113 549 555
20. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial Blood 2002 99 731 735
21. C hild JA M organ GJ D avies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue in multiple myeloma N Engl J Med 2003 348 1875 1883
22. R eece DE B redeson C P erez WS et al. Autologous stem cell transplantation in multiple myeloma patients <60 vs >60 years of age Bone Marrow Transplant 2003 32 1135 1143
23. B adros A B arlogie B S iegel E et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure Br J Haematol 2001 114 822 829
24. M ahendra P J ohnson D H ood IM et al. High-dose therapy and autologous stem cell rescue for poor risk and reftactory lymphoma: a single centre experience of 123 patients Bone Marrow Transplant 1996 17 973 978
25. R apoport AP L ifton R C onstine LS et al. Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): long-term follow-up and analysis of prognostic factors Bone Marrow Transplant 1997 19 883 890
26. K etterer N S onet A D umontet C et al. Toxicities after peripheral blood progenitor cell transplantation for lymphoid malignancies: analysis of 300 cases in a single institution Bone Marrow Transplant 1999 23 1309 1315
27. C opelan EA P enza SL P ohlman B et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma Bone Marrow Transplant 2000 25 1243 1248
28. T arella C C uttica C V itolo U et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the Intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence Cancer 2003 97 2748 2759
29. M ounier N G isselbrecht C Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's lymphoma Ann Oncol 1998 9 Suppl. 1 S15 S21
30. J antunen E I tälä M J uvonen E et al. Autologous stem cell transplantation in elderly (> 60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis Bone Marrow Transplant 2006 in press
31. V an Besien K T abocoff J R odriquez M et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity Bone Marrow Transplant 1995 15 549 555
32. F rassoni F L abopin M P owles R et al. Effect of centre on outcome of bone-marrow transplantation in acute myeloid leukaemia Lancet 2000 355 1393 1398
33. L oberiza FR Z hang MJ L ee SJ et al. Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States Blood 2005 105 2979 2987
34. T hieblemont C D umontet C S aad H et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma Bone Marrow Transplant 2002 30 869 775
35. S pencer A H orvath N G ibson J et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation Bone Marrow Transplant 2005 35 971 977
36. S pielberger R S tiff P B ensinger W et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers N Engl J Med 2004 351 2590 2598